Does the serum IL-17 titer influence the efficacy of interferon-β treatment in multiple sclerosis patients?;Nivelul seric al IL-17 influenţeazǎ eficacitatea tratamentului cu beta interferon la pacienţii cu sclerozǎ multiplǎ?

Revista Romana de Medicina de Laborator

Volumn 19, Issue 4, 2011, Pages 381-389

  Bǎlaşa, Rodica ^a   Huţanu, Adina ^a   Bajko, Z ^a   Feier, Camelia ^a   Pascu, I ^a  

^a University Emergency County Hospital   (Romania)

Author keywords

Interferon beta; Interleukine 17; Multiple sclerosis

Indexed keywords

EID: 84856286546     PISSN: 18416624     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
2. Korn T. Pathophysiology of multiple sclerosis. J Neurol 2008; 255: 2-6.
3. Rio J, Nos C, Tintoré M, Borrás C, Galán I, Combella M, et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon-β: implications for clinical trials. Ann Neurol 2002; 52: 400-406.
4. El-behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol 2010; 5: 189-197.
5. Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol 2009; 8: 545-559.
6. McDonald WI, Compson A, Edan G, Goodkin D, Hartung H-P, Lubin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
7. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846.
8. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the "McDonald Criteria". Ann Neurol 2011; 69: 292-302.
9. Pozzilli C, Prosperini L. Clinical markers of therapeutic response to disease modifying drugs. Neurol Sci 2008; 29: S211-S213.
10. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β. Ann Neurol 2009; 65: 499-509.
11. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467-476.
12. Fort MM, Cheung J, Yen D, Li J, Zurawaski SM, Lo S, et al. Il-25 induced Il-4, Il-5 and Il-13 and Th2-associated pathologies in vivo. Immunity 2001; 15: 985-995.
13. Weaver CT, Hatton RD, Mangan PR, Harrington LE. Il-17 family cytokines and the expanding diversity of effectors T cell lineages. Annu Rev Immunol 2007; 25: 821-852.
14. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, et al. Interleukin-17 production in central nervous system-infiltrating T cells in glial cells is associated with active disease in multiple sclerosis. Amer J Pathol 2008; 172: 146-155.
15. Weiner HL. A shift from adaptative to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 2008; 255: 3-11.
16. Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthansen J, Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009; 132: 3329-3341.
17. Axtell RC, de Jong BA, Boniface K, Van der Voort L, Bhat R R, De Sarno P, et al. T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010; 16: 406-412
18. Bǎlaşa R, Huţanu A, Feier C, Bajko Z, Pascu I. Incidence and clinical significance of binding and neutralizing antibodies induced by interferon-β treatment in patients with multiple sclerosis. Rev Rom Med Lab 2010; 19: 39-50.
19. Van der Voort L, Kok A, Visser A, Oudejans CBM, Caldono M, Gilli F, et al. Interferon-beta bioactivity measurement in multiple sclerosis: fesability for routine clinical practice. Multiple Sclerosis 2009; 15: 212-218.
20. Sominanda A, Hillert J, Fogdell-Hahn A. In vivo bioactivity of interferon-beta in multiple sclerosis with neutralizing antibodies is titer-dependent. J Neurol Neurosurg Psychiatry 2008; 79: 57-62.
21. Sørensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
22. Bertolotto A, Gilli F. Interferon-beta responders and nonresponders. A biological approach. Neurol Sci 2008; 29: S216-S217.
23. Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Di Sapio A, et al. Biological responsiveness to first injections of interferon-betain patients with multiple sclerosis. J Neuroimmunol 2005; 158: 195-203.
24. Furlan R. Definition of nonresponders: biological markers. Neurol Sci 2008; 29: S214-S215